Lumos Pharma Inc Revenue Growth Rates (LUMO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lumos Pharma Inc   (NASDAQ: LUMO)
 

LUMO's Revenue Growth by Quarter and Year

Lumos Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LUMO Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 0.73
2nd Quarter June 0.49
1st Quarter March 0.17
FY 1.39

LUMOs Annual Revenue
Lumos Pharma Inc 's Revenue in the fiscal year 2023 $ 2.05 millions
Lumos Pharma Inc 's Revenue in the fiscal year 2022 $ 1.52 millions
Lumos Pharma Inc 's Revenue in the fiscal year 2021 $ 0.23 millions
Lumos Pharma Inc 's Revenue in the fiscal year 2020 $ 0.17 millions
Lumos Pharma Inc 's Revenue in the fiscal year 2019 $ 0.94 millions




LUMO Revenue third quarter 2024 Y/Y Growth Comment
Lumos Pharma Inc achieved in the third quarter 2024, above Company average Revenue surge of 7160% year on year, to $ 0.73 millions.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Revenue growth. While Lumos Pharma Inc ' s Revenue doubling of 7160% ranks overall at the positon no. 10 in the third quarter 2024.


LUMO Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 62.75 % 131.82 % 450 %
3rd Quarter September 7160 % -98 % - -
2nd Quarter June -7.55 % 32.5 % 3900 % -66.67 %
1st Quarter March -75.36 % 527.27 % - -
FY   - 35.53 % 560.87 % -

Financial Statements
Lumos Pharma Inc 's third quarter 2024 Revenue $ 0.73 millions LUMO's Income Statement
Lumos Pharma Inc 's third quarter 2023 Revenue $ 0.01 millions Quarterly LUMO's Income Statement


LUMO Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 8200 % 2 % -
3rd Quarter September 48.16 % -98.11 % 25 % -
2nd Quarter June 188.24 % -23.19 % 263.64 % -
1st Quarter March -79.52 % 35.29 % -50 % -
FY (Year on Year)   - 35.53 % 560.87 % -


Back to LUMO Growth rate Comparisons >> Back to LUMO Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #6
Overall #10

Revenue Y/Y Growth Statistics
High Average Low
57466.33 % 1966.19 % -100 %
(June 30. 2015)   (Jun 30 2019)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #6
Overall #10
Revenue Y/Y Growth Statistics
High Average Low
57466.33 % 1966.19 % -100 %
(June 30. 2015)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Lumos Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11700 % 416.71 % -100 %
(Dec 31 2023)  


LUMO's III. Quarter Q/Q Revenue Comment
Lumos Pharma Inc achieved in the III. Quarter 2024 below company average Revenue jump of 48.16% quarter on quarter, to $ 0.73 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -98.11% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Lumos Pharma Inc 's Revenue growth quarter on quarter, overall rank is 218.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #67
Overall #218
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #67
Overall #218
Revenue Q/Q Growth Statistics
High Average Low
11700 % 416.71 % -100 %
(Dec 31 2023)  


LUMO's III. Quarter Q/Q Revenue Comment
Lumos Pharma Inc achieved in the III. Quarter 2024 below company average Revenue jump of 48.16% quarter on quarter, to $ 0.73 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -98.11% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Lumos Pharma Inc 's Revenue growth quarter on quarter, overall rank is 218.


Lumos Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 2.21 $ 1.49 $ 1.53 $ 2.05 $ 1.74
Y / Y Revenue Growth (TTM) 26.94 % -33.27 % -27.48 % 34.67 % 41.1 %
Year on Year Revenue Growth Overall Ranking # 352 # 38 # 178 # 172 # 448
Seqeuential Revenue Change (TTM) 48.38 % -2.56 % -25.65 % 18.08 % -22 %
Seq. Revenue Growth (TTM) Overall Ranking # 3520 # 400 # 199 # 354 # 310


Cumulative Revenue growth Comment
Although Lumos Pharma Inc 's Annual Revenue growth year on year were below company's average 1674.12% , Revenue announced in the Sep 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.94% year on year, from -33.27% in Jun 30 2024.

In the Healthcare sector 109 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 38 to 352.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 110
Overall # 352

Revenue TTM Y/Y Growth Statistics
High Average Low
19690.59 %
 1674.12 %
-206.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 504
S&P 500 # 3520
Cumulative Revenue growth Comment
Although Lumos Pharma Inc 's Annual Revenue growth year on year were below company's average 1674.12% , Revenue announced in the Sep 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.94% year on year, from -33.27% in Jun 30 2024.

In the Healthcare sector 109 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 38 to 352.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 110
Overall # 352

Revenue TTM Y/Y Growth Statistics
High Average Low
19690.59 %
1674.12 %
-206.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 504
S&P 500 # 3520




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LUMO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Iovance Biotherapeutics inc 12,385.07%$ 12,385.075 millions
Foxo Technologies Inc 11,860.00%$ 11,860.000 millions
Lumos Pharma Inc 10,271.43%$ 10,271.429 millions
Immunitybio inc 7,346.34%$ 7,346.341 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________3,777.07%$ 3,777.073 millions


About Lumos Pharma Inc Revenue Growth Rates (LUMO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lumos Pharma Inc (CIK 1126234).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001126234-24-000097
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lumos Pharma Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.